L3HYPDH

Across TCGA pan-cancer cohorts, L3HYPDH Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated L3HYPDH data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher L3HYPDH Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated L3HYPDH expression acts as an unfavorable survival marker.

LUSC, UCEC, and SKCM are the cancer types where L3HYPDH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.152	0.797	<.001	36	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	III,IV	0.233	0.705	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

L3HYPDH–LUSC (DFS)

Open the LUSC breakdown →